SequelSEC

REVELATION BIOSCIENCES, INC. REVB

Pharmaceutical Preparations · CIK 0001810560 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$9.07M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

REVELATION BIOSCIENCES, INC. (REVB) reported net income of -$8.91M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from REVELATION BIOSCIENCES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

REVELATION BIOSCIENCES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$9.07M-$7.98M-$8.66M-$10.86M-$11.95MUnavailableUnavailable
Net income-$8.91M-$15.04M-$120.25K-$10.83M-$11.99M-$1.63M-$3.64K
Research & development$4.06M$3.55M$4.15M$5.38M$6.91MUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable-$1.63MUnavailable
Income tax expense$0$0$0$0$0UnavailableUnavailable
Diluted EPS$-23.95$-1,052.16$-8.44$-149.20$-42.50UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$5.01M$4.43M$4.51M$5.49M$5.04M$145.49KUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

REVELATION BIOSCIENCES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$10.70M$6.50M$11.99M$5.25M$1.27M$11.73KUnavailable
Total assets$11.58M$6.62M$12.21M$5.50M$2.04M$74.16M$22.67K
Current assets$10.81M$6.57M$12.15M$5.41M$1.91M$651.29K$22.67K
Total liabilities$2.72M$1.91M$5.56M$4.45M$2.14M$6.34M$26.31K
Current liabilities$2.00M$1.91M$5.56M$4.45M$2.14M$3.43M$26.31K
Total equity incl. NCI$8.86M$4.71M$6.65M$1.05M-$99.47K$3.41M-$3.64K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$47.81M$73.51MUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$577.50K$783.62K$1.36M$554.20K$596.26K$33.77KUnavailable

Cash flow

REVELATION BIOSCIENCES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$8.27M-$18.32M-$7.29M-$11.22M-$11.09M-$216.66KUnavailable
Capital expendituresUnavailable$19.17KUnavailableUnavailable$131.96KUnavailableUnavailable
Investing cash flowUnavailable-$19.17KUnavailableUnavailable-$131.96K-$74.04MUnavailable
Financing cash flow$12.47M$12.85M$14.03M$15.20M$8.00M$74.26MUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailable$11.73KUnavailable
Stock-based compensation$595.37K$168.85K$155.72K$301.12K$470.88KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable$35.50MUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

REVELATION BIOSCIENCES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailable-$18.34MUnavailableUnavailable-$11.22MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio5.41x3.43x2.18x1.22x0.89x0.19x0.86x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open REVB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2021-12-31

Difference 47811164 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2020-12-31

Difference 9103653 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.